Skip to main content

Real world evidence (RWE) offers an opportunity to conduct timely, large, low-cost studies to answer important clinical questions that may not always be feasible to investigate using randomized controlled trials for practical, financial or ethical reasons. However, RWE research also faces several important challenges.

One of these is unmeasured confounding that can invalidate comparisons between different treatment groups. While unmeasured confounders cannot, by definition, be measured, in this webinar we will discuss several indicators of unmeasured confounding that can help determine whether outcomes of a particular treatment group can be accurately compared to others. These will include:

  • positive and negative control outcomes;
  • distribution of known confounders; and
  • clinically unexpected temporal relationships.

Discussion of these methods will be illustrated on the example of a multi-center PCORI-funded BESTMED study that investigated optimal 2nd line therapy of type 2 diabetes.

Presenters

Lucia Petito, PhD
Assistant Professor of Biostatistics
Northwestern University's Feinberg School of Medicine
Alexander Turchin, MD, MS
Brigham and Women's Hospital and Harvard Medical School
Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School